These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11950959)

  • 1. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.
    Chernicky CL; Tan H; Yi L; Loret de Mola JR; Ilan J
    Mol Pathol; 2002 Apr; 55(2):102-9. PubMed ID: 11950959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo.
    Chernicky CL; Yi L; Tan H; Gan SU; Ilan J
    Cancer Gene Ther; 2000 Mar; 7(3):384-95. PubMed ID: 10766344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-type plasminogen activator is upregulated in metastatic breast cancer cells exposed to insulin-like growth factor-I.
    Chernicky CL; Yi L; Tan H; Ilan J
    Clin Breast Cancer; 2005 Oct; 6(4):340-8. PubMed ID: 16277885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
    Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
    J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.
    Burfeind P; Chernicky CL; Rininsland F; Ilan J; Ilan J
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7263-8. PubMed ID: 8692980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines.
    Nakamura K; Hongo A; Kodama J; Miyagi Y; Yoshinouchi M; Kudo T
    Cancer Res; 2000 Feb; 60(3):760-5. PubMed ID: 10676665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid.
    Neuenschwander S; Roberts CT; LeRoith D
    Endocrinology; 1995 Oct; 136(10):4298-303. PubMed ID: 7664648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells.
    Scotlandi K; Maini C; Manara MC; Benini S; Serra M; Cerisano V; Strammiello R; Baldini N; Lollini PL; Nanni P; Nicoletti G; Picci P
    Cancer Gene Ther; 2002 Mar; 9(3):296-307. PubMed ID: 11896447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
    Nielsen TO; Andrews HN; Cheang M; Kucab JE; Hsu FD; Ragaz J; Gilks CB; Makretsov N; Bajdik CD; Brookes C; Neckers LM; Evdokimova V; Huntsman DG; Dunn SE
    Cancer Res; 2004 Jan; 64(1):286-91. PubMed ID: 14729636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability.
    Guerra FK; Eijan AM; Puricelli L; Alonso DF; Bal de Kier Joffé E; Kornblihgtt AR; Charreau EH; Elizalde PV
    Int J Cancer; 1996 Mar; 65(6):812-20. PubMed ID: 8631597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor II receptor, transforming growth factor-beta, and Cdk4 expression and the developmental epigenetics of mouse palate morphogenesis and dysmorphogenesis.
    Melnick M; Chen H; Buckley S; Warburton D; Jaskoll T
    Dev Dyn; 1998 Jan; 211(1):11-25. PubMed ID: 9438420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
    Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
    Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.
    Mohanam S; Jasti SL; Kondraganti SR; Chandrasekar N; Kin Y; Fuller GN; Lakka SS; Kyritsis AP; Dinh DH; Olivero WC; Gujrati M; Yung WK; Rao JS
    Clin Cancer Res; 2001 Aug; 7(8):2519-26. PubMed ID: 11489835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
    Dunn SE; Torres JV; Oh JS; Cykert DM; Barrett JC
    Cancer Res; 2001 Feb; 61(4):1367-74. PubMed ID: 11245436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
    Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA.
    Resnicoff M; Li W; Basak S; Herlyn D; Baserga R; Rubin R
    Cancer Immunol Immunother; 1996 Jan; 42(1):64-8. PubMed ID: 8625368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells.
    Yang JM; Chen WS; Liu ZP; Luo YH; Liu WW
    J Gastroenterol Hepatol; 2003 Mar; 18(3):296-301. PubMed ID: 12603530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro suppression of urokinase plasminogen activator in breast cancer cells--a comparison of two antisense strategies.
    Arens N; Gandhari M; Bleyl U; Hildenbrand R
    Int J Oncol; 2005 Jan; 26(1):113-9. PubMed ID: 15586231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors.
    Resnicoff M; Sell C; Rubini M; Coppola D; Ambrose D; Baserga R; Rubin R
    Cancer Res; 1994 Apr; 54(8):2218-22. PubMed ID: 8174129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.